EGFR
EGFR (epidermal growth factor receptor) inhibitors are compounds that block the signaling of EGFR, a receptor that is often overexpressed in various cancers and plays a critical role in angiogenesis. EGFR inhibitors are used to prevent tumor growth and metastasis by disrupting the pathways that promote blood vessel formation in tumors. These inhibitors are widely used in cancer research and therapy. At CymitQuimica, we offer a diverse selection of high-quality EGFR inhibitors to support your research in oncology and angiogenesis.
Found 594 products of "EGFR"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Andamertinib
CAS:Andamertinib is an EGFR inhibitor with antitumor activity.Formula:C31H36N8O3Color and Shape:SolidMolecular weight:568.669EGFR/BRAF-IN-1
EGFR/BRAF-IN-1 inhibits EGFR/BRAF (BRAFV600E IC50: 45 nM, GI50: 35 nM) and has antioxidant properties.Formula:C26H28ClN3O4Color and Shape:SolidMolecular weight:481.97EGFR-IN-23
CAS:EGFR-IN-23, identified as compound 8 in WO2021244502A1, is a potent EGFR tyrosine kinase inhibitor (TKI) demonstrating an inhibitory concentration (IC50) of 8.Formula:C36H44BrN10O3PColor and Shape:SolidMolecular weight:775.68HER2-IN-9
HER2-IN-9, an oral HER2 inhibitor (IC50: 0.03 μM), hinders growth and spread of HER2+ breast cancer.Formula:C19H14BrF3N2OColor and Shape:SolidMolecular weight:423.23BML-265
CAS:BML-265 is a potent inhibitor of EGFR tyrosine kinase (EGFR tyrosine kinase). It disrupts Golgi apparatus integrity in human cells and hinders the transport of secretory proteins across various substances. In contrast, BML-265 does not affect the integrity and transport of the Golgi apparatus in rodent cells.Formula:C18H15N3O2Color and Shape:SolidMolecular weight:305.331EGFR/HER2/DHFR-IN-1
Potent EGFR/HER2/DHFR inhibitor for MCF-7 breast cancer; IC50: 0.153/0.108/0.291 μM; arrests G1/S phase, triggers apoptosis.Formula:C14H11BrN4O2SColor and Shape:SolidMolecular weight:379.23HER2-IN-8
CAS:HER2-IN-8 is an inhibitor of HER-2 that can be used in the study of cancer and inflammation-related diseases.Formula:C26H25F2N9O3Color and Shape:SolidMolecular weight:549.53EGFR/HER2-IN-8
EGFR/HER2-IN-8 inhibits EGFR, HER2, DHFR (IC50: 0.45, 0.244, 5.669 μM); useful in cancer research, safe and selective.Formula:C16H16N4O2SColor and Shape:SolidMolecular weight:328.39HER2-IN-21
CAS:<p>HER2-IN-21 (compound 657994) is an inhibitor of the human epidermal growth factor receptor 2 (HER2) with an IC50 value of 3.85 μM.</p>Formula:C20H18N4O3SColor and Shape:SolidMolecular weight:394.447NSC381467
CAS:NSC381467: Potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.Formula:C20H16O7Color and Shape:SolidMolecular weight:368.34EGFR ligand-14
CAS:EGFRligand-14 serves as an EGFR ligand and is utilized in the synthesis of SJF-1521.Formula:C27H19ClFN3OColor and Shape:SolidMolecular weight:455.91EGFR-IN-160
CAS:EGFR-IN-160 is an EGFR inhibitor with IC50 values of 1.62, 0.49, and 0.98 μM for EGFRWT, EGFRT790M, and EGFRL858R/T790M/C797S, respectively. It can induce cell cycle arrest at the G2/M and S phases and apoptosis (Apoptosis) in NCI-H522 cells, demonstrating anticancer properties. Additionally, EGFR-IN-160 exhibits antioxidant activity against DPPH (IC50: 12.11 µM) and H2O2 (IC50: 8.89 µM).Formula:C15H12N2O4Color and Shape:SolidMolecular weight:284.27Sacibertinib
CAS:Sacibertinib inhibits Trk, targeting EGFR-TK (EC50 110 nM) & HER2 (EC50 244 nM), with anticancer properties.Formula:C32H31ClN6O4Color and Shape:SolidMolecular weight:599.08EGFR-IN-147
CAS:EGFR-IN-147 (compound ID-5841161) is a potent EGFR inhibitor, demonstrating a 14% inhibition rate at a concentration of 1μM. It holds promise for cancer research applications.Formula:C13H13N5OColor and Shape:SolidMolecular weight:255.275JBJ-02-112-05
CAS:JBJ-02-112-05 is a potent, mutant-selective, allosteric and orally active inhibitor of EGFR with an IC 50 of 15 nM for EGFR L858R/T790M [1].Formula:C27H20N4O2SPurity:98%Color and Shape:SolidMolecular weight:464.54EGFR-IN-34
EGFR-IN-34 is a low-toxicity, acrylamide derivative antitumor agent that is a potent inhibitor of EGFR.Formula:C26H27ClN6O2Color and Shape:SolidMolecular weight:490.98JBJ-09-063
CAS:JBJ-09-063: EGFR inhibitor, IC50s 0.147-0.396 nM for various mutants; hinders EGFR/Akt/ERK1/2 phosphorylation; targets TKI-sensitive/resistant lung cancer.Formula:C31H29FN4O3SColor and Shape:SolidMolecular weight:556.65EG31
CAS:EG31 is an EGFR inhibitor that effectively suppresses the proliferation of triple-negative breast cancer (TNBC) cells by inhibiting the EGFR signaling pathway. It demonstrates a GI50 value of 498.90 nM for MDA-MB-231 cells and 740.73 nM for Hs578T cells, while also inducing apoptosis. Additionally, EG31 retains its antiproliferative activity against 5-fluorouracil (5-FU) resistant TNBC cells, with a GI50 of 519.5 nM. EG31 is applicable in research on TNBC resistance.Formula:C30H13Br2N3O6Color and Shape:SolidMolecular weight:671.25HER2-IN-6
CAS:HER2-IN-6, a potent HER2 inhibitor, may target wild/mutant EGFR and HER2-mediated tumors. (Patent WO2021164697A1, compound 11)Formula:C26H32N8O3Color and Shape:SolidMolecular weight:504.58EGFR-IN-58
EGFR-IN-58 is a potent, selective, ATP-competitive inhibitor of EGFR. EGFR-IN-58 exhibits significant cytotoxicity against melanoma, colon and blood cancers.Formula:C31H30FN7OColor and Shape:SolidMolecular weight:535.61EGFR/HER2-IN-4
EGFR/HER2-IN-4: oral, irreversible dual EGFR inhibitor (IC50: 0.6 nM), targets L858R/T790M mutations, potent anti-lung cancer effects in vivo.Color and Shape:SolidTesevatinib tosylate
CAS:Tesevatinib tosylate (XL-647 tosylate) is an orally administered epidermal growth factor receptor (EGFR) inhibitor that can cross the blood-brain barrier. It significantly reduces cell viability with IC50 values of 11 nM and 102 nM in GBM12 and GBM6, respectively. Additionally, Tesevatinib tosylate inhibits HER2 (IC50=16.1 nM), VEGFR2 (IC50=1.5 nM), and Src (IC50=10.3 nM), demonstrating antitumor activity by inhibiting tumor proliferation.Formula:C31H33Cl2FN4O5SColor and Shape:SolidMolecular weight:663.59EGFR-IN-132
CAS:EGFR-IN-132 (Compound 23) is an EGFR inhibitor effective against various EGFR mutations including the wild-type, L858R/T790M, d19/T790M, L858R/T790M/C797S, and d19/T790M/C797S with IC50 values of 1.6, 0.025, 0.019, 0.022, and 0.029 nM, respectively. This compound demonstrates favorable pharmacokinetics with high oral bioavailability.Formula:C27H31N7O3Color and Shape:SolidMolecular weight:501.58HER2-IN-12
HER2-IN-12 is an HER2 inhibitor with an IC50 value of 121 nM and can be used to study cancers such as breast cancer.Formula:C17H18BrN5O2SColor and Shape:SolidMolecular weight:436.33D-69491 hydrochloride
CAS:D-69491 hydrochloride is an inhibitor of HER-2 tyrosine kinase activity, blocking the phosphorylation of HER-2 and inhibiting the proliferation of SKOV-3 cells. It exhibits antitumor activity.Formula:C25H26Cl2FN7O3Color and Shape:SolidMolecular weight:562.42EGFR-IN-130
EGFR-IN-130 (compound 14b) is an EGFR inhibitor and an inducer of apoptosis (apoptoosis). It effectively kills HeLa cancer cells by inducing apoptosis.Formula:C27H25N3O6SColor and Shape:SolidMolecular weight:519.57EGFR-IN-135
EGFR-IN-135 (compound 3d) is an EGFR inhibitor with an IC50 value of 0.086 µM. It inhibits cell growth and arrests the cell cycle in the S phase in breast cancer cell lines.Formula:C12H14N4OS2Color and Shape:SolidMolecular weight:294.4EGFR-IN-125
CAS:<p>EGFR-IN-125 (example 37) is a potent EGFR inhibitor with IC50 values of <0.3 nM for EGFR(d746-750/T790M/C797S), 0.52 nM for EGFR(L858R/T790M/C797S), 0.5 nM for EGFR(d746-750/C797S), 0.69 nM for EGFR(L858R/C797S), and 0.92 nM for EGFR (wild type).</p>Formula:C30H26N8OColor and Shape:SolidMolecular weight:514.58Si306
CAS:Si306, an Src inhibitor, exhibits antitumor activity by reducing the phosphorylation of focal adhesion kinase (FAK) and the expression of epidermal growth factor receptor (EGFR), thereby inhibiting the invasion of human glioblastoma (GBM).Formula:C25H26BrClN6OSColor and Shape:SolidMolecular weight:573.94EGFR-IN-149
CAS:EGFR-IN-149 (Compound 3-OH) is an EGFR inhibitor with an IC50 value of 0.42 nM.Formula:C16H15N3OSColor and Shape:SolidMolecular weight:297.375EGFR/HER2-IN-5
<p>EGFR/HER2-IN-5: Irreversible, oral dual EGFR inhibitor, IC50 0.6 nM, targets L858R/T790M mutations, anti-tumor in vivo for lung cancer study.</p>Color and Shape:SolidEGFR-IN-35
CAS:EGFR-IN-35, an acrylamide-based EGFR inhibitor, shows promise for EGFR mutation-related cancers like NSCLC.Formula:C25H24ClN7O2Color and Shape:SolidMolecular weight:489.96LSD1/EGFR-IN-1
CAS:<p>LSD1/EGFR-IN-1 (compound L-1) is an effective inhibitor of LSD1, EGFRT790M/L858R, and EGFRL858R/T790M/C797S, with IC50 values of 6.24, 2.06, and 5.01 μM, respectively. This compound plays a significant role in cancer research.</p>Formula:C21H20ClN3O4Color and Shape:SolidMolecular weight:413.854EGFR-IN-7
CAS:<p>EGFR-IN-7 (TQB3804) is a selective and potent EGFR kinase inhibitor.</p>Formula:C32H41BrN9O2PPurity:95.32% - 99.64%Color and Shape:SolidMolecular weight:694.6TLC9995-0188
CAS:Tyrosine-protein kinase ABL, IC50: 1500 nMFormula:C16H15N5Color and Shape:Yellow SolidMolecular weight:277.331Nimotuzumab (powder)
CAS:<p>Nimotuzumab (powder) is a humanized IgG1 monoclonal antibody that specifically targets the epidermal growth factor receptor (EGFR), possessing a dissociation constant (KD) of 0.21 nM. It blocks the binding to its ligand by targeting the extracellular domain of EGFR. Nimotuzumab exhibits strong antitumor activity by inducing both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), exerting cytolytic effects on target tumors.</p>Color and Shape:LiquidImbotolimod
Imbotolimod, a humanized monoclonal antibody of the immunoglobulin G1-kappa class, exhibits both anti-ERBB2 and antineoplastic activities.Color and Shape:Odour LiquidHMBD-001
<p>HMBD-001 is a humanized IgG1 monoclonal antibody inhibitor that targets HER3. By inhibiting the dimerization of HER3, HMBD-001 suppresses the growth and proliferation of tumor cells. It holds potential for research in cancer treatments, specifically for pancreatic cancer and non-small cell lung cancer.</p>Color and Shape:Odour LiquidOlmutinib
CAS:Olmutinib (BI1482694) is a Novel Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorFormula:C26H26N6O2SPurity:99.14%Color and Shape:SolidMolecular weight:486.59Duligotuzumab
CAS:<p>Duligotuzumab (MEHD-7945A) is a bispecific humanised IgG-κ monoclonal antibody targeting HER3 and EGFR, solid tumours, head and neck cancer,colorectal cancer.</p>Purity:95%Color and Shape:LiquidRef: TM-T80604
Discontinued productEGFR-IN-82
CAS:<p>EGFR-IN-82 (Compound 8a) is a potent, orally active inhibitor of EGFR, exhibiting IC50 values of 0.09 nM for EGFR L858R/T790M/C797S and 0.06 nM for EGFR Del19/</p>Formula:C32H41BrN9O2PPurity:98%Color and Shape:SolidMolecular weight:694.6YK-029A
CAS:<p>YK-029A, an orally active EGFR mutant inhibitor, targets both EGFR T790M and EGFRex20ins mutations.</p>Formula:C27H32N8O2Purity:98%Color and Shape:SolidMolecular weight:500.6EGFR-IN-122
CAS:<p>EGFR-IN-122 (compound Yfq07) serves as a potent inhibitor of EGFR. It effectively inhibits the proliferation of PC-9GR and HCC827GR cells.</p>Formula:C19H20N4O3Color and Shape:SolidMolecular weight:352.39Ref: TM-T200157
Discontinued productEGFR-IN-123
CAS:<p>EGFR-IN-123 (compound D06) is an effective EGFR inhibitor. It exhibits inhibitory activity against several cell lines including PC-9G, A549, A431, and HCT116, with IC50 values of 0.74, 1.36, 1.20, and 2.53 μM respectively.</p>Formula:C24H27F3N6OColor and Shape:SolidMolecular weight:472.51Ref: TM-T200485
Discontinued product
